nach oben

International Journal of Clinical Oncology

Erschienen in:

01.02.2015 | Original Article

Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?

verfasst von: Ahmet Dirican, Betul Bolat Kucukzeybek, Ahmet Alacacioglu, Yuksel Kucukzeybek, Cigdem Erten, Umut Varol, Isil Somali, Lutfiye Demir, Ibrahim Vedat Bayoglu, Yasar Yildiz, Murat Akyol, Betul Koyuncu, Eyup Coban, Eda Ulger, Fulya Cakalagaoglu Unay, Mustafa Oktay Tarhan

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of mortality in patients with cancer. Similarly, a study in a large series has shown that the newly defined derived NLR (dNLR; neutrophil/leukocyte–lymphocyte ratio) also has prognostic value. The present study retrospectively evaluates the prognostic significance of NLR and dNLR in breast cancer.

Methods

Hematological parameters and clinicopathological data during diagnosis were retrospectively recorded for 1,527 patients diagnosed with breast cancer at Izmir Katip Celebi University Ataturk Research and Training Hospital from January 2006 to December 2011. The cut-off values were determined by calculating the NLR and dNLR of the patients.

Results

The cut-off values were determined as 4 and 2 for NLR and dNLR, respectively. The association between NLR and dNLR assessed by Spearman’s rank correlation analysis was 0.935 (P < 0.001). There was a significant difference regarding disease free survival (DFS) and overall survival (OS) in patients with NLR <4 and NLR ≥4 (respectively, P < 0.00, P < 0.001). Similarly, there was a significant difference regarding DFS and OS in patients with dNLR <2 and dNLR ≥2 (respectively, P < 0.001, P < 0.001). Furthermore, NLR and dNLR demonstrated a significant association with the American Joint Committee on Cancer (AJCC) staging (P < 0.001). Assessment using the Cox proportional multivariate model showed that high NLR, pN, pT, luminal A-like, luminal B-like (HER2 positive), basal-like, and AJCC staging are independent prognostic factors.

Discussion

NLR was shown to be better than dNLR in terms of predicting prognosis in patients with breast cancer. However, large prospective studies are required to further demonstrate the prognostic significance of these two values.

Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236PubMedCrossRef

Page DL (1991) Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 15(4):334–349PubMedCrossRef

Rosen PP, Groshen S, Kinne DW et al (1993) Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11(11):2090–2100PubMed

Simpson JF, Page DL (1995) Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 103(1):115

Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):966–978PubMed

Rakha EA, El-Sayed ME, Lee AH et al (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26(19):3153–3158PubMedCrossRef

Fisher B, Redmond C, Fisher ER et al (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076–1087PubMed

Tandon AK, Clark GM, Chamness GC et al (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7(8):1120–1128PubMed

Andrulis IL, Bull SB, Blackstein ME et al (1998) Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4):1340–1349PubMed

10.

Ferrero-Poüs M, Hacène K, Bouchet C et al (2000) Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 6(12):4745–4754PubMed

11.

Grann VR, Troxel AB, Zojwalla NJ et al (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103(11):2241–2251PubMedCrossRef

12.

Mantovani A, Allavena P, Sica A et al (2008) Cancer related inflammation. Nature 454(7203):436–444PubMedCrossRef

13.

Hilmy M, Bartlett JMS, Underwood MA et al (2005) The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 92(4):625–627PubMedCentralPubMedCrossRef

14.

Crumley AB, McMillan DC, McKernan M et al (2006) An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 94(11):1568–1571PubMedCentralPubMed

15.

Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6):1028–1030PubMedCentralPubMedCrossRef

16.

Proctor MJ, Talwar D, Balmar SM et al (2010) The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 103:870–876PubMedCentralPubMedCrossRef

17.

Schmidt H, Bastholt L, Geertsen P et al (2005) Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 93(3):273–278PubMedCentralPubMedCrossRef

18.

Cho H, Kim JH (2009) Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. Biomarkers 14(3):161–170PubMedCrossRef

19.

Sadik CD, Kim ND, Luster AD (2011) Neutrophils cascading their way to inflammation. Trends Immunol 32(10):452–460PubMedCentralPubMedCrossRef

20.

Miskolci V, Rollins J, Vu HY et al (2007) NFkappaB is persistently activated in continuously stimulated human neutrophils. Mol Med 13(3–4):134–142PubMedCentralPubMed

21.

Calkins CM, Bensard DD, Shames BD et al (2002) IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. J Endotoxin Res 8(1):59–67PubMed

22.

Leitch EF, Chakrabarti M, Crozier JE et al (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 97(9):1266–1270PubMedCentralPubMedCrossRef

23.

Millrud CR, Månsson Kvarnhammar A, Uddman R et al (2012) The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival. PLoS One 7(12):e51120PubMedCentralPubMedCrossRef

24.

Ma JP, Wang Z, Lin JW et al (2011) Neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 14(12):944–947PubMed

25.

Wang S, Zhang Z, Fang F et al (2011) The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett 2(4):735–740PubMedCentralPubMed

26.

Ishizuka M, Nagata H, Takagi K et al (2012) Clinical significance of tumor pathology for postoperative survival of patients undergoing surgery for stage IV colorectal cancer. Anticancer Res 32(8):3291–3297PubMed

27.

Proctor MJ, McMillan DC, Morrison DS et al (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699PubMedCentralPubMedCrossRef

28.

Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145PubMedCrossRef

29.

Goldhirsch A, Winer EP, Coates AS et al (2013) Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223PubMedCentralPubMedCrossRef

30.

Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329PubMedCentralPubMedCrossRef

31.

Azab B, Bhatt VR, Phookan J et al (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19(1):217–224PubMedCrossRef

32.

Chua W, Charles KA, Baracos VE et al (2011) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104(8):1288–1295PubMedCentralPubMedCrossRef

33.

Keizman D, Ish-Shalom M, Huang P et al (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48(2):202–208PubMedCentralPubMedCrossRef

Titel: Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?
verfasst von: Ahmet Dirican
Betul Bolat Kucukzeybek
Ahmet Alacacioglu
Yuksel Kucukzeybek
Cigdem Erten
Umut Varol
Isil Somali
Lutfiye Demir
Ibrahim Vedat Bayoglu
Yasar Yildiz
Murat Akyol
Betul Koyuncu
Eyup Coban
Eda Ulger
Fulya Cakalagaoglu Unay
Mustafa Oktay Tarhan
Publikationsdatum: 01.02.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 1/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0672-8

Springer Medizin

Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?